RxDoctor Payments Data

Hunt Anderson, MD

Interventional Cardiology · Crossville, TNNPI 1770508756

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,300 of the $58,510 with a category attached, or 92.8%. Boehringer Ingelheim accounts for 73.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $26,418 and has fallen 99.6% since, to $93 in 2025.

$58,510in general payments, 2019–2025

Across 187 payments — averaging $312.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$43K
  • Lilly USA, LLC$13K
  • Johnson & Johnson$327
  • AstraZeneca$295
  • Amgen$226
  • Boston Scientific$201
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$54,30093%
  • Travel & lodging$9152%
  • Food & beverage$3,2966%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,510 in reported general payments places this provider in the 85th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$65,919
Medicare patients
371
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$29,344
JardianceEmpagliflozin17$24,066
EntrestoSacubitril/Valsartan15$20,760
BrilintaTicagrelor14$11,953
Rosuvastatin Calcium153$2,842
Valsartan41$2,750
Metoprolol Succinate53$1,086
Carvedilol117$916
ClopidogrelClopidogrel Bisulfate61$708
Losartan Potassium51$499
Prasugrel Hcl19$336
Isosorbide Mononitrate ErIsosorbide Mononitrate12$301
Famotidine18$217
Doxazosin Mesylate11$189
Ezetimibe11$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$29,34421 claims
Boehringer IngelheimJardiance$43,054$24,06617 claims
NovartisEntresto$125$20,76015 claims
AstraZenecaBrilinta$295$11,95314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →